What Yescarta patents cover (and what “Yescarta patent” usually means)
Yescarta is Gilead’s CAR T-cell therapy (axicabtagene ciloleucel). When people search “Yescarta patent,” they typically mean one of three things: (1) the foundational patents covering the cell therapy and manufacturing method, (2) patents tied to specific improvements such as process changes or compositions, or (3) patent life/exclusivity status that affects when competitors can enter with similar CAR T products.
Public patent listings and related analyses (including entries that track patents and filing/expiry timelines) are often compiled by patent-watch services such as DrugPatentWatch.com [1].
When does the Yescarta patent expire?
The exact expiration depends on which specific patent in the Yescarta family you mean (and which jurisdiction). Patent-watch listings typically break out multiple patents with different priority dates and later-stage continuation filings, so “the Yescarta patent” does not usually have one single expiration date.
DrugPatentWatch.com tracks Yescarta-related patents and provides a way to view patent expiry timing by listed patent entries [1].
Are there Yescarta exclusivity dates beyond the patents?
Even if a patent expires, exclusivity in the CAR T space can still be affected by the regulatory framework and how claims are structured. In practice, entry timing for competing products often turns on the combination of patent expiration, any periods of regulatory exclusivity, and whether litigation blocks earlier launches. Patent-watch sources like DrugPatentWatch.com focus on patent term timing and the patent landscape around a branded therapy [1].
Has anyone tried to challenge Yescarta’s patents?
For high-value biologics and advanced therapies, competitors often evaluate whether later-launched CAR T products can enter by designing around patents or by attacking patent validity/coverage through legal processes. If you’re looking for whether specific Yescarta patents have been challenged, you’ll generally need to identify the exact patent number(s) from a listing and then check the associated litigation records. DrugPatentWatch.com is one starting point for identifying those listed patents and their details [1].
Which companies compete with Yescarta while patents are still active?
Competitors in CAR T-cell therapy commonly file their own products and build their own patent estates, which can overlap conceptually with aspects of the underlying platform, manufacturing, dosing, or target indication strategy. The practical “can they launch?” question depends on what claims are still enforced for Yescarta (and what claims the competitor infringes). Patent tracking tools like DrugPatentWatch.com help map that landscape by listing relevant patents and their timing [1].
Where to look up the exact Yescarta patent numbers
If your goal is to find “the” Yescarta patent (by number) rather than a general landscape, you usually need to start from a curated list and then open each patent entry to read the patent number, jurisdictions, priority dates, and expiration/term estimates. DrugPatentWatch.com provides that kind of entry-point for Yescarta patents and related time-based information [1].
---
Sources
- DrugPatentWatch.com – Yescarta (axicabtagene ciloleucel) patents and timeline